Mathieu Bui the Thuong

Procurement And Logistics Manager USA at Evotec

Mathieu BUI THE THUONG is a seasoned procurement and logistics manager with extensive experience in the life sciences sector, currently serving at Evotec since November 2015. In this role, Mathieu implements and manages purchasing processes while negotiating contracts for lab equipment, reagents, and consumables. Previous positions include lead buyer at Sanofi, where a comprehensive spend analysis was conducted for over 800 suppliers, and junior buyer at Daiichi-Sankyo France, focusing on marketing expenditures. Early career experience includes a research scientist role at NovAliX and a research assistant position at Université Pierre et Marie Curie. Mathieu BUI THE THUONG holds a Master's in International Purchasing Management from emlyon business school and a Doctorate in Organic Chemistry from the University of Strasbourg, alongside multiple degrees in chemistry and biology from Pierre and Marie Curie University.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Evotec

5 followers

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.


Industries

Headquarters

Hamburg, Germany

Employees

1,001-5,000

Links